EXHIBIT 11. STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
The computation of net income per share for the three and six months ended
June 30, 1994 and 1993 is as follows (000's omitted except per share
amounts):
Three months ended Six months ended
June 30, June 30,
1994 1993 1994 1993
-------------------- -------------------
Primary
-------
Net loss $(6,832) $(2,966) $(11,377) $(1,903)
Reduced earnings due to
dilution in ownership
which would result upon
the exercise of options
and warrants currently
outstanding to purchase
common shares of
subsidiaries (2) (8) (11) (4)
-------- -------- --------- --------
$(6,834) $(2,974) $(11,388) $(1,907)
======== ======== ========= ========
Average common shares
outstanding 20,529 20,416 20,526 19,135
Dilutive common equivalent
issuable upon the exercise
of options and warrants
currently outstanding to
purchase common shares of
ICN Pharmaceuticals, Inc. - - - -
-------- -------- --------- --------
20,529 20,416 20,526 19,135
======== ======== ========= ========
Net loss per share $ (.33) $ (.15) $ (.55) $ (.10)
======== ======== ========= ========
(continued)
EXHIBIT 11. STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS (continued)
The computation of net income per share for the three and six months ended
June 30, 1994 and 1993 is as follows (000's omitted except per share
amounts):
Three months ended Six months ended
June 30, June 30,
1994 1993 1994 1993
-------------------- -------------------
Fully Diluted
-------------
Net loss $(6,832) $(2,966) $(11,377) $(1,903)
Reduced earnings due to
dilution in ownership
which would result upon
the exercise of options
and warrants currently
outstanding to purchase
common shares of
subsidiaries (2) (8) (11) (4)
Interest expense on
convertible debt 555 798 1,099 1,625
-------- -------- -------- --------
$(6,279) $(2,176) $(10,289) $ (282)
======== ======== ========= ========
Average common shares 20,529 20,416 20,526 19,135
outstanding
Dilutive common equivalent
shares issuable upon the
exercise of options and
warrants currently
outstanding to purchase
common shares of ICN
Pharmaceuticals, Inc. 294 556 314 754
Conversion of debentures 2,827 3,441 2,827 3,441
-------- -------- -------- --------
23,650 24,413 23,667 23,330
======== ======== ======== ========
Net loss per share $ (.27) $ (.09) $ (.43) $ (.01)
======== ======== ======== ========